High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16-23 years) were enrolled in a randomised, placebo-controlled study of a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2, and 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling for HPV DNA, serum anti-HPV testing, and Pap testing, with follow-up biopsy as indicated. A subset of 241 subjects underwent two further years of follow-up. At 5 years post enrollment, the combined incidence of HPV 6/11/16/18-related persistent infection or disease was reduced in vaccine-recipients by 96% (two cases vaccine versus 46 placebo). There were no cases of HPV 6/11/16/18-related precancerous cervical dysplasia or genital warts in vaccine recipients, and six cases in placebo recipients (efficacy = 100%; 95% CI:12-100%). Through 5 years, vaccine-induced anti-HPV geometric mean titres remained at or above those following natural infection. In conclusion, a prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18. This duration supports vaccination of adolescents and young adults, which is expected to greatly reduce the burden of cervical and genital cancers, precancerous dysplasia, and genital warts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
Classification of papillomaviruses
de Villiers, E.-M., Fauquet, C., Broker, T. R., Bernard, H.-U., & zur Hausen, H. (2004) · Virology · doi:10.1016/j.virol.2004.03.033 · Cited by 3,193
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104 · cited 1×
“…of genital wart cases (Wiley et al, 2002) and recurrent respiratory papillomatosis, an aggressive, highly morbid and occasionally fatal disease manifested as rapidly growing benign laryngeal tumours that cause airway obstruction (Somers et al, 1997; Derkay and Darrow, 2000; Green et al, 2000).”
BackgroundHarper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Self-citationVilla, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Self-citationThe Pap Test and Bethesda 2014
Nayar, R., & Wilbur, D. C. (2015) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2015.03.003 · Cited by 1,144
Clifford, G., Gallus, S., Herrero, R., Muñoz, N., Snijders, P., Vaccarella, S., Anh, P., Ferreccio, C., Hieu, N., Matos, E., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67069-9 · Cited by 1,093
Winer, R. L. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwf180 · Cited by 1,044
Cited by
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationArbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Garland, S. M., Harper, D. M., Tang, G. W., Ferris, D. G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60777-6 · Cited by 581
Self-citationMarkowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit192 · Cited by 521
Olsson, S.-E., Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.049 · Cited by 454
Self-citationHPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 429
Forhan, S. E., Gottlieb, S. L., Sternberg, M. R., Xu, F., Datta, S. D., McQuillan, G. M., Berman, S. M., & Markowitz, L. E. (2009) · Pediatrics · doi:10.1542/peds.2009-0674 · Cited by 427
Dobson, S. R. M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D. W., Kollmann, T. R., Halperin, S. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1625 · Cited by 417
Einstein, M. H., Baron, M., Levin, M. J., Chatterjee, A., Edwards, R. P., Zepp, F., Carletti, I., Dessy, F. J., Trofa, A. F., Schuind, A., et al. (2009) · Human Vaccines · doi:10.4161/hv.5.10.9518 · Cited by 402
Human papillomavirus vaccines: WHO position paper
WHO (2009) · Biologicals · doi:10.1016/j.biologicals.2009.04.005 · Cited by 357
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.002 · Cited by 334
Self-citationQuadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Self-citationKjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0031 · Cited by 328
Self-citationParents' health beliefs and HPV vaccination of their adolescent daughters
Reiter, P. L., Brewer, N. T., Gottlieb, S. L., McRee, A.-L., & Smith, J. S. (2009) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.05.024 · Cited by 319
Reisinger, K. S., Block, S. L., Lazcano-Ponce, E., Samakoses, R., Esser, M. T., Erick, J., Puchalski, D., Giacoletti, K. E. D., Sings, H. L., Lukac, S., et al. (2007) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000253970.29190.5a · Cited by 296
Self-citationLu, B., Kumar, A., Castellsagué, X., & Giuliano, A. R. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-13 · Cited by 283
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Jit, M., Choi, Y. H., & Edmunds, W. J. (2008) · BMJ · doi:10.1136/bmj.a769 · Cited by 273
Burden of cervical cancer in the United States, 1998-2003
Watson, M., Saraiya, M., Benard, V., Coughlin, S. S., Flowers, L., Cokkinides, V., Schwenn, M., Huang, Y., & Giuliano, A. (2008) · Cancer · doi:10.1002/cncr.23756 · Cited by 271
Immunobiology of HPV and HPV vaccines
Stanley, M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.003 · Cited by 271
Insinga, R. P., Liaw, K.-L., Johnson, L. G., & Madeleine, M. M. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2922 · Cited by 267
Adelstein, D. J., Ridge, J. A., Gillison, M. L., Chaturvedi, A. K., D'Souza, G., Gravitt, P. E., Westra, W., Psyrri, A., Martin Kast, W., Koutsky, L. A., et al. (2009) · Head & Neck · doi:10.1002/hed.21269 · Cited by 261
Di Mario, S., Basevi, V., Lopalco, P. L., Balduzzi, S., D’Amico, R., & Magrini, N. (2015) · Journal of Immunology Research · doi:10.1155/2015/435141 · Cited by 257
Cervical cancer in India and HPV vaccination
Kaarthigeyan, K. (2012) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.96961 · Cited by 254
Brewer, N. T., Gottlieb, S. L., Reiter, P. L., McRee, A.-L., Liddon, N., Markowitz, L., & Smith, J. S. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181f12dbf · Cited by 254
Clinician's guide to human papillomavirus immunology: knowns and unknowns
Einstein, M. H., Schiller, J. T., Viscidi, R. P., Strickler, H. D., Coursaget, P., Tan, T., Halsey, N., & Jenkins, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70108-2 · Cited by 226
Fairley, C. K., Hocking, J. S., Gurrin, L. C., Chen, M. Y., Donovan, B., & Bradshaw, C. S. (2009) · Sexually Transmitted Infections · doi:10.1136/sti.2009.037788 · Cited by 223
Prophylactic HPV vaccination: past, present, and future
CASTLE, P. E., & MAZA, M. (2016) · Epidemiology and Infection · doi:10.1017/s0950268815002198 · Cited by 201
The role of human papillomaviruses in carcinogenesis
Ghittoni, R. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.526 · Cited by 198
“A recent clinical study aiming at directly comparing the two vaccines has clearly demonstrated that so far both products showed high efficacy in preventing the development of cervical pre-malignant lesions, inducing a robust response in immunised individuals and providing protection for at least five years [54, 61, 62…”
BackgroundFactors affecting transmission of mucosal human papillomavirus
Veldhuijzen, N. J., Snijders, P. J., Reiss, P., Meijer, C. J., & van de Wijgert, J. H. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70190-0 · Cited by 180
Integrating clinical, community, and policy perspectives on human papillomavirus vaccination
Fernández, M. E., Allen, J. D., Mistry, R., & Kahn, J. A. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103609 · Cited by 97
The predicted impact of vaccination on human papillomavirus infections in Australia
Smith, M. A., Canfell, K., Brotherton, J. M. L., Lew, J., & Barnabas, R. V. (2008) · International Journal of Cancer · doi:10.1002/ijc.23633 · Cited by 54
“100% effective in protecting susceptible individuals against HPV 16 infection when given in the recommended 3-dose schedule, consistent with HPV vaccine trial results demonstrating almost complete protection against persistent HPV 16/18 infection and related CIN in women uninfected prior to completion of vaccination.(…”
ResultHuman papillomavirus infection among young adolescents in India: Impact of vaccination
Hussain, S., Bharadwaj, M., Nasare, V., Kumari, M., Sharma, S., Hedau, S., & Das, B. C. (2012) · Journal of Medical Virology · doi:10.1002/jmv.22261 · Cited by 46
Prevalence of human papillomavirus types in cervical lesions from women in rural Western India
Deodhar, K., Gheit, T., Vaccarella, S., Romao, C. C., Tenet, V., Nene, B. M., Jayant, K., Kelkar, R., Malvi, S. G., Sylla, B. S., et al. (2012) · Journal of Medical Virology · doi:10.1002/jmv.23310 · Cited by 34
Metadata
- Authors
- Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., Andersson-Ellstrom, A., Elfgren, K., Krogh, G. V., Lehtinen, M., Malm, C., Tamms, G. M., Giacoletti, K., Lupinacci, L., Railkar, R., Taddeo, F. J., Bryan, J., Esser, M. T., Sings, H. L., Saah, A. J., & Barr, E.
- Venue
- British Journal of Cancer
- Published
- 2006-11-21
- Volume
- 95
- Issue
- 11
- Pages
- 1459-1466
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1992519297
- Cited by
- 806
- References
- 31
- FWCI
- 73.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.